Between SRS and FSRT cohorts, no significant differences were seen in age, gender, rate of GTR, resection prior to radiation, prior cranial radiation, KI-67 indexes, volume of the radiation field, isodose prescription, max dose, mean dose, median follow-up duration, radiation morbidities, tumor recurrence, or recurrence free survival. This evidence concerns the gene MKI67 and neoplasm.